| | Clinicopathological parameters | Values |
| | Age (years); Mean ± SD | 52.18 ± 12.19 | | Age groups | | ≤35 years, n (%) | 16 (11.4) | | 36–50 years, n (%) | 52 (37.1) | | >50 years, n (%) | 72 (51.4) | | Follow up duration (months); Mean ± SD | 4.14 ± 1.88 | | Tumor laterality | | Right breast, n (%) | 78 (55.7) | | Left breast, n (%) | 62 (44.3) | | Type of biopsy | | Trucut, n (%) | 48 (34.3) | | Modified radical mastectomy, n (%) | 40 (28.6) | | Breast conversion surgery, n (%) | 22 (15.7) | | Simple mastectomy, n (%) | 30 (21.4) | | Tumor size (cm), n = 92; Mean ± SD | 5.99 ± 3.44 | | Tumor (T) stage, n = 92 | | T1, n (%) | 12 (13) | | T2, n (%) | 34 (37) | | T3, n (%) | 46 (50) | | Tumor grade | | Grade 2, n (%) | 34 (24.3) | | Grade 3, n (%) | 106 (75.7) | | Squamous differentiation | | Present, n (%) | 96 (68.6) | | Absent, n (%) | 44 (31.4) | | Chondroid differentiation | | Present, n (%) | 8 (5.7) | | Absent, n (%) | 132 (94.3) | | Spindle cell differentiation | | Present, n (%) | 16 (11.4) | | Absent, n (%) | 124 (88.6) | | Nodal (N) stage, n = 92 | | N0, n (%) | 52 (56.5) | | N1, n (%) | 18 (19.6) | | N2, n (%) | 9 (9.8) | | N3, n (%) | 13 (14.1) | | Recurrence | | Yes, n (%) | 44 (31.4) | | No, n (%) | 96 (68.6) | | Survival status | | Alive, n (%) | 100 (71.4) | | Expired, n (%) | 40 (28.6) | | ER/PR | | Positive, n (%) | 46 (32.9) | | HER2/neu | | Positive, n (%) | 32 (22.9) | | Negative, n (%) | 108 (77.1) |
|
|
